Filer Snapshot

IBERE PHARMACEUTICALS

CIK 0001835205. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

51

Latest filing

13 Mar 2023

Industry

Blank Checks

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Go to filings Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing 15-12G

15-12G filed on 13 Mar 2023 for CIK 0001835205.

View Source Filing
Identity 2 identity fields
SEC industry
Blank Checks (Office of Real Estate and Construction)
Business address
2005 Market Street, Suite 2030, Philadelphia, PA, 19103
SEC profile fields 2 profile fields
State of incorporation
Cayman Islands
Fiscal year-end
31 December

Filer intelligence

What SEC filings say about IBERE PHARMACEUTICALS

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

SEC source mix

Counts show available parsed rows, not one combined ownership total.

No XML rows yet
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

No parsed ownership summary yet

We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.

Latest update

What changed recently for IBERE PHARMACEUTICALS

New fact period available

Latest financial period: Q3 2022. Open the source-backed page to inspect the fresh filing or facts context.

Update date

14 Nov 2022

Page type

Company facts

Latest period

Q3 2022

SEC-backed company facts were refreshed from filings filed on 14 Nov 2022.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

IBERE PHARMACEUTICALS has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q3 2022. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 14 Nov 2022.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001835205 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
51
First seen
07 Dec 2020
Latest filing
13 Mar 2023
Entity
Company

Observed form types

15-12G 25-NSE 8-K SC 13G SC 13G/A 10-Q 10-K 10-Q/A 8-K/A NT 10-Q +13 more

Primary evidence

Open SEC filing index IBERE PHARMACEUTICALS SEC filings IBERE PHARMACEUTICALS company facts

Industry context: Blank Checks.

Latest Filings

Showing the latest 12 of 51 SEC filings for IBERE PHARMACEUTICALS.

Open full filing history
15-12G File 001-40119

15-12G

Filing date
13 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-40119

25-NSE filing

Filing date
02 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92346

SC 13G filing

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92346

SC 13G/A

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92346

IBER 13G

Filing date
08 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92346

SCHEDULE 13G (AMENDMENT NO. 1)

Filing date
08 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92346

SC 13G/A

Filing date
02 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .